About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD1.70
- USD1.73
- USD1.59
- USD4.02
- 11.10%
- --
- 413.97k
- 906.96k
- 82M
- 1.14
- -38.80%
Stock News
yesterday
Why Zelle scams concern lawmakers so much — and how they could affect you
MarketWatch
yesterday
Innocan Pharma Submits Investigational New Animal Drug Application to FDA's Veterinary Center
Yahoo
yesterday
Search competition fears hit Alphabet stock yet again. We see no reason to join the sellers
CNBC
yesterday
ATI Physical Therapy to Announce Second Quarter 2024 Financial Results
Yahoo
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
